Title |
Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment
|
---|---|
Published in |
OncoTargets and therapy, June 2012
|
DOI | 10.2147/ott.s23273 |
Pubmed ID | |
Authors |
Viktor Grünwald, Axel S Merseburger |
Abstract |
The landscape of renal cell carcinoma (RCC) treatment has changed dramatically during recent years. Bevacizumab/interferon, sunitinib, sorafenib, temsirolimus, everolimus, and pazopanib have been proven effective in metastatic RCC. Axitinib is a novel tyrosine kinase inhibitor, which inhibits the vascular endothelial growth factor receptor (VEGFR) at subnanomolar level. Based on this extraordinary VEGFR inhibition, axitinib is considered a next-generation agent. The recent AXIS trial reported on axitinib's efficacy in second line treatment of RCC, which led to its recent approval in the USA. This review focuses on the clinical efficacy of axitinib in RCC patients. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Switzerland | 1 | 3% |
Unknown | 28 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 5 | 17% |
Other | 3 | 10% |
Professor > Associate Professor | 3 | 10% |
Student > Ph. D. Student | 3 | 10% |
Student > Doctoral Student | 2 | 7% |
Other | 5 | 17% |
Unknown | 8 | 28% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 9 | 31% |
Agricultural and Biological Sciences | 5 | 17% |
Biochemistry, Genetics and Molecular Biology | 1 | 3% |
Business, Management and Accounting | 1 | 3% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 3% |
Other | 4 | 14% |
Unknown | 8 | 28% |